Octapharma

Profile narrative

Octapharma USA is engaged in the collection of human plasma and the manufacture of plasma-derived therapeutic proteins for patients in the United States and internationally. The company operates a network of plasma donation centers where source plasma is gathered from volunteer donors. This plasma is then fractionated into products such as immunoglobulins, clotting factors, and albumin, which are used to treat immunodeficiency, bleeding disorders, and other serious medical conditions. Octapharma USA serves healthcare providers, hospitals, and specialty clinics that rely on these plasma-based medicines. Its activities are regulated by the U.S. Food and Drug Administration and adhere to stringent quality and safety standards.

While the exact size of Octapharma USA’s workforce or number of donation centers is not disclosed in the available information, the organization maintains a presence across multiple states and is part of the broader Octapharma group, which has manufacturing and research facilities in Europe and other regions. The incident reported on April 17, 2024, highlighted that Octapharma USA’s U.S. plasma donation centers were temporarily suspended due to suspicious network activity, whereas European donation centers and production sites continued normal operations, underscoring a geographic separation in operational impact. Octapharma’s distinguishing attributes include its specialization in plasma-derived biologics, its integration of donation, fractionation, and distribution processes, and its role as a supplier of critical therapies that require compliance with both FDA and international regulatory frameworks. The organization emphasizes donor safety and the quality of collected plasma through rigorous screening and testing procedures. Structurally, Octapharma USA functions as the United States‑based division of the global Octapharma enterprise, aligning its strategies with the parent company’s mission to advance plasma‑based medicine.

Incidents

1 incident linked to this organisation.